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Abstract
Objective
To evaluate for racial diﬀerences in triggering receptor expressed on myeloid cells 2 (TREM2),
a key immune mediator in Alzheimer disease, the levels of CSF soluble TREM2 (sTREM2),
and the frequency of associated genetic variants were compared in groups of individuals who
self-reported their race as African American (AA) or non-Hispanic White (NHW).
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Methods
Community-dwelling older research participants underwent measurement of CSF sTREM2
concentrations and genetic analyses.
Results
The primary cohort included 91 AAs and 868 NHWs. CSF sTREM2 levels were lower in the
AA compared with the NHW group (1,336 ± 470 vs 1,856 ± 624 pg/mL, p < 0.0001). AAs were
more likely to carry TREM2 coding variants (15% vs 3%, p < 0.0001), which were associated
with lower CSF sTREM2. AAs were less likely to carry the rs1582763 minor allele (8% vs 37%,
p < 0.0001), located near MS4A4A, which was associated with higher CSF sTREM2. These
ﬁndings were replicated in an independent cohort of 23 AAs and 917 NHWs: CSF sTREM2
levels were lower in the AA group (p = 0.03), AAs were more likely to carry coding TREM2
variants (22% vs 4%, p = 0.002), and AAs were less likely to carry the rs1582763 minor allele
(16% vs 37%, p = 0.003).
Conclusions
On average, AAs had lower CSF sTREM2 levels compared with NHWs, potentially because
AAs are more likely to carry genetic variants associated with lower CSF sTREM2 levels.
Importantly, CSF sTREM2 reﬂects TREM2-mediated microglial activity, a critical step in the
immune response to amyloid plaques. These ﬁndings suggest that race may be associated with
risk for genetic variants that inﬂuence Alzheimer disease–related inﬂammation.
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Glossary
AA = African American; AD = Alzheimer disease; ADNI = Alzheimer’s Disease Neuroimaging Initiative; ADRC = Alzheimer
Disease Research Center; ANCOVA = analysis of covariance; CDR = Clinical Dementia Rating; NfL = neuroﬁlament light
chain; NHW = non-Hispanic White; PC1 = principal component 1; pTau = phosphorylated tau 181; sTREM2 = soluble
TREM2; TREM2 = triggering receptor expressed on myeloid cells 2; tTau = total tau.

Alzheimer disease (AD) dementia aﬀects people of all races
and ethnicities.1 Recent studies have found that key proteins
associated with AD, including CSF total tau (tTau) and
phosphorylated tau 181 (pTau), vary between groups of individuals by self-reported race.2–5 Importantly, race is a social
identity and does not always segregate with genetic markers of
ancestry.6 Associations with race are aﬀected by numerous
nongenetic inﬂuences, including factors that aﬀect health such
as socioeconomic status,7 education,8 and stress.9 However,
when individuals are grouped by self-reported race, African
Americans (AAs) and non-Hispanic Whites (NHWs) have
diﬀerent frequencies of some gene variants known to modify
risk for AD dementia.10
In the brain, triggering receptor expressed on myeloid cells 2
(TREM2) is expressed by microglia and is a key mediator of
the innate immune response to amyloid plaques.11,12 Multiple
coding variants in the TREM2 gene have been associated with
increased AD risk13–15 and are hypothesized to impair
TREM2 function.16 The p.R47H and p.R62H variants, which
are associated with AD risk in individuals of European
ancestry,13,14 are less frequent in AA.17 CSF soluble TREM2
(sTREM2) is a biomarker of TREM2-mediated microglial
activity,18–20 and CSF sTREM2 concentrations have been
associated with some variants in TREM221 and MS4A4A,22 a
gene that is also associated with AD risk.22,23 It is unknown
whether average CSF sTREM2 levels vary in individuals
grouped by racial identity.
We evaluated whether CSF sTREM2 and genetic variants
known to be associated with CSF sTREM2 levels vary between AA and NHW groups. CSF sTREM2 concentrations,
the frequencies of TREM2 coding variants, and the frequencies of 2 single nucleotide polymorphisms in or near MS4A4A
were compared in AA and NHW groups.

Methods
Participants
The primary cohort for this study was from the Knight Alzheimer Disease Research Center (ADRC), which includes
one of the largest groups of AA in AD research with both CSF
biomarker and genetic data.4 This cohort consists of
community-dwelling older adults, including participants with
and without cognitive impairment, enrolled in research
studies of memory and aging at Washington University in St.
Louis. The cohort was recruited for research participation
only and was not clinic-based. Most participants lived in the
2
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greater St. Louis metropolitan area, which is approximately
18% AAs and 77% NHWs.4 Recruitment methods included
word of mouth from individuals who were already participants, community presentations and other outreach eﬀorts,
and occasionally physician referral. Eligibility criteria included
the absence of major medical conditions (e.g., metastatic
cancer) that could interfere with longitudinal participation,
but common chronic medical conditions (e.g., hypertension,
diabetes, and depression) were permitted. The participants
underwent annual clinical and cognitive assessments using the
Uniform Data Set24 that includes the Clinical Dementia
Rating (CDR)25 and Mini-Mental State Examination.26 The
CDR and etiologic diagnosis of the cause(s) of dementia
when present was made by the clinician in accordance with
standard criteria and methods24 without reference to the
participant’s performance on neuropsychological tests, the
results of prior assessments, or biomarker results. Race, sex,
and family history of AD were self-reported. Data were used
for research purposes only.
After analyses of the Knight ADRC cohort were complete, an
independent cohort was examined to determine whether the
major ﬁndings could be replicated (racial diﬀerences in CSF
sTREM2 and associated genetic variants). Data used for the
replication cohort were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. The ADNI
was launched in 2003 as a public-private partnership, led by
Principal Investigator Michael W. Weiner, MD. For a full
description of the ADNI cohort and protocols, see adni-info.org.
Participants in both the Knight ADRC and ADNI cohorts met
the following criteria: (1) race was self-reported as either AA
or NHW and (2) CSF sTREM2, Aβ42, tTau, and pTau
measurements were available within 1 year of a clinical assessment. No participants were represented in both cohorts.
Standard Protocol Approvals, Registrations,
and Patient Consents
Written informed consent was obtained from all participants
and their study partners. All procedures were approved by
Washington University’s Human Research Protection Oﬃce.
Sequencing and Genotyping
The APOE genotype was determined by genotyping rs7412
and rs429358 using TaqMan genotyping technology.27
TREM2 variants were determined by pooled DNA sequencing.15 The rs1582763 and rs6591561 polymorphisms associated with MS4A4A were genotyped using Illumina arrays.15
Neurology.org/NG

Principal components were computed using genome-wide
genotyping data.28 Estimates of African ancestry for each individual were established with the ﬁrst principal component
(PC1) which diﬀerentiates European and African ancestry.29
A higher PC1 value corresponds to greater African ancestry.
CSF Collection and Analysis
Methods for the Knight ADRC cohort are described here;
for the ADNI cohort, the methods were similar and are
described in detail online at adni-info.org. Lumbar puncture was performed as previously described.30 For CSF
samples collected before October 11, 2016, Aβ42, tTau,
and pTau were measured with the corresponding Elecsys
assays on a Roche Cobas e 601 analyzer.30 Elecsys data
were not available for samples collected more recently
(October 13, 2016, through February 12, 2019), but Aβ42,
tTau, and pTau were measured with the corresponding
INNOTEST (Fujirebio) assays. Neuroﬁlament light chain
(NfL) was measured with an immunoassay kit manufactured by Uman Diagnostics. Concentrations of sTREM2
were measured with the same immunoassay in both the
Knight ADRC and ADNI cohorts.22 To decrease plate-toplate variability due to potential matrix eﬀects, sTREM2
values were normalized using high and low pooled controls
and bridging samples.22
Statistical Analysis
For analyses involving CSF Aβ42, tTau, and pTau, only values
obtained with Elecsys assays (87% of samples) were used
because it is unclear whether INNOTEST values are comparable to those measured by Elecsys. CSF biomarker concentrations were transformed with the natural logarithm for
visualization, analysis, and covariate adjustment. Characteristics of AA and NHW groups were compared using Student t
tests for continuous variables and χ 2 tests or Fisher exact tests
for categorical variables. The signiﬁcance of diﬀerences in
CSF biomarker values between AA and NHW groups was
calculated by Mann-Whitney tests for unadjusted raw values
and Student t tests for natural logarithm-transformed values.
Comparisons of CSF biomarkers were performed with Student t tests of the natural logarithm-transformed value unless
otherwise speciﬁed. Spearman correlations were performed
between natural logarithm-transformed CSF biomarker concentrations and PC1 because PC1 was not normally
distributed.
Analysis of covariance (ANCOVA) models were implemented using natural logarithm-transformed CSF biomarker
concentrations as the outcome variable. Predictors in the
ANCOVA models were based on previously published
models4 and included the following: race (AA or NHW),
centered age (the age at CSF collection minus the mean age
for the cohort [69.0 years]), sex, years of education (dichotomized as ≤12 and >12 years of education), family history
of dementia status (positive or negative, only available for the
Knight ADRC cohort), APOE e4 status (carrier or noncarrier), dementia status (CDR = 0 or CDR >0), and every
Neurology.org/NG

2-way interaction among these variables. Genetic variant
status (carrier or noncarrier) and the interaction of genetic
variant status with all other covariates were entered into the
CSF sTREM2 model to obtain covariate-adjusted p values for
each genetic variant. In the model incorporating both TREM2
coding variant status and rs1582763 minor allele (A) carrier
status, the interaction between these variants was also
included.
Statistical analyses were implemented using SAS 9.4 (SAS
Institute Inc., Cary, NC). Plots were created with GraphPad
Prism version 7.04 (GraphPad Software, La Jolla, CA). All p
values were from 2-sided tests, and results were deemed statistically signiﬁcant at p < 0.05.
Data Availability
Data are available to qualiﬁed investigators on request to the
Knight ADRC (knightadrc.wustl.edu/Research/ResourceRequest.htm) and ADNI (adni.loni.usc.edu/data-samples/accessdata/).

Results
Participants
The Knight ADRC cohort consisted of 959 participants who
met the inclusion criteria: 91 AAs and 868 NHWs (table 1).
The AA group was younger than the NHW group (66.1 ± 8.2
vs 69.3 ± 9.2 years, p = 0.002), less likely to have dementia
(13% vs 25%, p = 0.01), less likely to have a family history of
dementia (44% vs 56%, p = 0.03), and reported slightly fewer
years of education (15.2 ± 2.9 vs 15.9 ± 2.7, p = 0.02). The
ADNI cohort consisted of 940 participants who met the inclusion criteria: 23 AAs and 917 NHWs (table 2). The AA
group reported fewer years of education compared with the
NHW group (14.9 ± 2.5 vs 16.1 ± 2.8, p = 0.04), but did not
diﬀer signiﬁcantly by age or dementia status.
Differences in CSF Biomarkers by Self-Reported
Race or Genetic Ancestry
Concentrations of CSF biomarkers including sTREM2 were
examined as a function of race. In the Knight ADRC cohort,
there was no diﬀerence in CSF Aβ42 concentrations (ﬁgure
1A) between AA and NHW groups. However, CSF tTau,
pTau, NfL, and sTREM2 levels were lower in the AA compared with the NHW group (p < 0.0001 for all) (ﬁgure 1, C, E,
G, and I). CSF biomarker levels were also examined as a
function of the PC1 measure of African genetic ancestry. PC1
was not correlated with CSF Aβ42 (ﬁgure 1B), but was correlated with CSF tTau, pTau, NfL, and sTREM2 (p < 0.0001
for all) (ﬁgure 1, D, F, H, and J), with lower levels of these
biomarkers associated with higher African genetic ancestry.
Even after adjusting for age, sex, years of education, family
history of dementia, APOE e4 status, dementia status, and
every 2 way interaction among these variables, there were
highly signiﬁcant reductions in CSF tTau, pTau, NfL, and
sTREM2 in the AA compared with the NHW group (p <
Neurology: Genetics | Volume 7, Number 2 | April 2021
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Table 1 Characteristics of Individuals in the Knight Alzheimer Disease Research Center Cohort
African American participants

Non-Hispanic White participants

Characteristic

n

n

Age at CSF collection, y

91

66.1 ± 8.2

868

69.3 ± 9.2

0.002

Sex, n (% female)

91

50 (55)

868

473 (55)

N.S.

Years of education

91

15.2 ± 2.9

868

15.9 ± 2.7

0.02

APOE «4 status, n (% carrier)

90

39 (43)

863

348 (40)

N.S.

CDR 0/0.5/1/2 (% >0)

91

79/8/4/0 (13)

868

647/177/39/5 (25)

0.01

MMSE (of 30)

91

28.5 ± 2.5

868

28.3 ± 2.5

N.S.

Family history, n (% positive)

91

40 (44)

868

489 (56)

0.03

TREM2 variant carriers, n (%)

91

14 (15)

868

28 (3)

<0.0001

rs1582763 genotype AA/AG/GG (minor allele [A] frequency)

89

1/13/75 (8)

843

106/407/330 (37)

<0.0001

rs6591561 genotype GG/AG/AA (minor allele [G] frequency)

88

9/31/48 (28)

851

73/355/423 (29)

N.S.

p Value

Abbreviations: CDR = Clinical Dementia Rating, where CDR = 0 indicates cognitive normality and CDR = 0.5, 1, 2, or 3 indicates very mild, mild, moderate, or
severe dementia, repectively; MMSE = Mini-Mental State Examination, where a score of 30 is “best” and a score of 0 is “worst”; N.S. = not significant.
Continuous measures are presented as the mean ± SD. The significance of differences between groups was determined by Student t tests for continuous
variables and by χ2 or Fisher exact tests for categorical variables. See figure 2 for a listing of specific TREM2 variants by race.

0.0001, <0.0001, 0.0005, and <0.0001, respectively, table 3
and tables e-1 to e-5, links.lww.com/NXG/A399). Race did
not interact signiﬁcantly with APOE e4 in these models, but
among APOE e4 carriers, pTau and tTau concentrations were
lower in the AA compared with the NHW group (p = 0.0001
and p < 0.0001, respectively). In contrast, among APOE e4
noncarriers, there were no signiﬁcant racial diﬀerences in
pTau and tTau concentrations.
Because the AA and NHW groups in the Knight ADRC cohort had signiﬁcant diﬀerences in some major covariates (age,

years of education, presence of dementia, and family history of
AD), an alternative approach was performed to evaluate
whether diﬀerences in CSF biomarker levels as a function of
race were a result of inadequate statistical correction for
covariates. A computer algorithm matched each AA participant, if possible, with 1 NHW participant by closest age
(within 3 years), years of education (within 2 years), presence
of dementia (CDR = 0 or CDR >0), and family history of AD.
NHW matches were available for 86 of 91 AA participants
(table e-6, links.lww.com/NXG/A399). In this subcohort
where there were no signiﬁcant diﬀerences between the AA

Table 2 Characteristics of Individuals in the Alzheimer’s Disease Neuroimaging Initiative Cohort
African American participants

Non-Hispanic White participants

Characteristic

n

n

Age at CSF collection, y

23

73.8 ± 7.4

917

73.3 ± 7.2

N.S.

Sex, n (% female)

23

13 (57)

917

393 (43)

N.S.

Years of education

23

14.9 ± 2.5

917

16.1 ± 2.8

0.04

APOE «4 status, n (% carrier)

23

11 (48)

917

441 (48)

N.S.

CDR 0/0.5/1 (% >0)

23

9/11/3 (61)

917

265/551/101 (71)

N.S.

TREM2 variant carriers, n (%)

23

5 (22)

917

35 (4)

0.002

rs1582763 genotype AA/AG/GG (minor allele [A] frequency)

22

0/7/15 (16)

913

130/424/359 (37)

0.003

rs6591561 genotype GG/AG/AA (minor allele [G] frequency)

23

3/9/11 (33)

917

83/402/432 (31)

N.S.

p Value

Abbreviations: CDR = Clinical Dementia Rating, where CDR = 0 indicates cognitive normality and CDR = 0.5, 1, 2, or 3 indicates very mild, mild, moderate, or
severe dementia, respectively; N.S. = not significant.
Continuous measures are presented as the mean ± SD. The significance of differences between groups was determined by Student t tests for continuous
variables and by χ2 or Fisher exact tests for categorical variables. See figure 2 for a listing of specific TREM2 variants by race.
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Figure 1 Differences in CSF Biomarker Concentrations by Self-Reported Race

The natural logarithm of CSF concentrations of
amyloid-β 42 (Aβ42, A, B), total tau (tTau, C, D),
phosphorylated tau 181 (pTau, E, F), neurofilament light chain (NfL, G, H), and soluble triggering receptor expressed on myeloid cells 2
(sTREM2, I, J) was plotted as a function of selfreported race (African American [AA] or nonHispanic White [NHW]) or a measure of African
genetic ancestry (PC1, higher values correspond
to higher African genetic ancestry, axis is reversed). Corresponding concentrations in pg/mL
are shown on the right axis. Red squares represent samples from AAs, and gray circles represent samples from NHWs. The number of
individuals in each group is listed (n).

and NHW groups by major covariates, the AA group had
lower CSF tTau, pTau, and sTREM2 compared with the
NHW group (p < 0.0001 for all).
Neurology.org/NG

In the ADNI cohort, the power to detect racial diﬀerences in
CSF biomarkers was much lower because of the smaller size of
the AA group (n = 23 AA in the ADNI cohort vs n = 91 AA in
Neurology: Genetics | Volume 7, Number 2 | April 2021
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the Knight ADRC cohort). There were no signiﬁcant racial differences in concentrations of CSF Aβ42, tTau, pTau, or NfL,
likely because the cohort was insuﬃciently powered to see these
smaller eﬀects. However, even with such a small AA group, CSF
sTREM2 concentrations were signiﬁcantly lower in the AA
compared with the NHW group (p = 0.001), and PC1 was
correlated with CSF sTREM2 (p = 0.0005) (table 4). After
adjusting for covariates, the racial diﬀerence in CSF sTREM2
remained signiﬁcant (p = 0.03). In the ADNI cohort, the AA and
NHW groups were relatively well matched for covariates, so no
matching secondary analysis was performed.
Concordance of Self-Reported Race and
Genetic Ancestry
Genetic ancestry data were available for 937 of 959 individuals
(98%) in the Knight ADRC cohort and all individuals in the
ADNI cohort. In both cohorts, only 1 individual was discordant;
in both cases, the individual identiﬁed as NHW but had a PC1
consistent with high African genetic ancestry. Because selfreported race and genetic ancestry were almost completely
concordant in these 2 cohorts (99.9%), analyses using either
measure resulted in nearly identical ﬁndings. Self-reported race
was used as the primary categorical measure of race because race
is a social rather than a genetic categorization. In addition, most
individuals (patients and potential research participants) cannot
provide a quantitative measure of their genetic ancestry (e.g.,
PC1), but they can report their racial identity. Most clinical trials
for AD recruit racial and ethnic groups based on self-reported
race, not on GWAS data. Therefore, self-reported race is more
broadly relevant to individuals and to other research studies.
Differences in TREM2 Coding Variants and
MS4A4A Polymorphisms by Self-Reported Race
The frequency of TREM2 coding variant status (any coding
variant vs wild-type sequence) in the AA and the NHW groups
was compared. AAs were more likely than NHWs to carry a
TREM2 coding variant in both the Knight ADRC cohort (15% vs
3%, p < 0.0001) and the ADNI cohort (22% vs 4%, p = 0.002).
This diﬀerence was primarily driven by a higher frequency of the
p.T96K, p.L211P, and p.W191X variants in the AA group; these
variants were in linkage disequilibrium.
The frequencies of 2 polymorphisms in the MS4A4A gene region
that have been associated with CSF sTREM2 concentrations
were evaluated. The minor allele (A) of rs1582763, an intergenic
variant located near MS4A4A, was less frequent in the AA than
the NHW group in both the Knight ADRC cohort (minor allele
frequency 8% vs 37%, p < 0.0001) and the ADNI cohort (16% vs
37%, p = 0.003). In contrast, the frequency of the rs6591561
minor allele (G) in MS4A4A was not signiﬁcantly diﬀerent in the
AA and NHW groups in the Knight ADRC cohort (28% vs 29%)
or the ADNI cohort (33% vs 31%).
Effects of Coding TREM2 Variants and rs1582763
on CSF sTREM2 Concentrations
As detailed above, AAs were more likely to carry a TREM2
coding variant and less likely to carry the rs1582763 minor
6
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allele (A). We examined how these genetic factors aﬀected
concentrations of CSF sTREM2 in the better-powered
Knight ADRC cohort. Individuals carrying a TREM2 coding
variant had lower CSF sTREM2 concentrations (ﬁgure 2A)
(p < 0.0001 before and p = 0.02 after covariate adjustment),
and individuals carrying the minor allele (A) of rs1582763 had
higher sTREM2 concentrations (ﬁgure 2B) (p < 0.0001 before and after covariate adjustment).
We hypothesized that the diﬀerence between AA and NHW
groups in CSF sTREM2 concentrations was largely explained
by the diﬀerent frequencies of TREM2 coding variants and
rs1582763 (A). The eﬀects of carrying a TREM2 coding
variant and/or rs1582763 (A) were additive such that TREM2
coding variant carriers and rs1582763 (A) noncarriers had the
lowest CSF sTREM2 levels (ﬁgure 2C). In the Knight ADRC
cohort, a model for CSF sTREM2 was implemented that
included race, TREM2 coding variant carrier status,
rs1582763 (A) carrier status, and all covariates and interactions. After accounting for these 2 genetic factors and covariates, concentrations of CSF sTREM2 were not signiﬁcantly
diﬀerent in AA and NHW groups (table e-7, links.lww.com/
NXG/A399), implying that racial diﬀerences in the frequencies of coding TREM2 variants and rs1582763 (A) were a
major driver of racial diﬀerences in CSF sTREM2 levels.
Similar trends were seen in the ADNI cohort (ﬁgure e-1),
although the small size of the AA cohort did not provide
adequate power for a complex analysis. In summary, the lower
average concentrations of CSF sTREM2 in AA may be related
to the higher frequency of coding TREM2 variants and the
lower frequency of the rs1582763 minor allele (A).

Discussion
In the Knight ADRC cohort, which includes one of the largest
groups of AA in AD research with both CSF biomarker and
genetic data, we found that the AA group had lower average
CSF sTREM2 levels compared with the NHW group. Our
analyses suggested that the lower CSF sTREM2 levels in AA
could be related to diﬀerences in genetic variant frequencies
between AA and NHW groups: AAs had a higher frequency of
TREM2 coding variants, which were associated with lower
CSF sTREM2; and AAs had a lower frequency of rs1582763
(A), which was associated with higher CSF sTREM2. After
these diﬀerences were found in the Knight ADRC cohort, the
ADNI cohort was evaluated speciﬁcally to determine whether
these diﬀerences could be replicated, reducing the possibility
of false discovery. Although the sizes of the AA groups in both
cohorts were relatively small, the ﬁndings in both the Knight
ADRC and ADNI cohorts were similar and highly statistically
signiﬁcant. Identiﬁcation of diﬀerences in even small cohorts
is important, as it may justify larger and more comprehensive
studies.
The diﬀerences we reported were between racial groups, but
there are likely numerous individual-level factors that modify
Neurology.org/NG

Table 3 CSF Biomarker Values of Individuals in the Knight Alzheimer Disease Research Center Cohort

Characteristic

AA participants

NHW participants

n

n

p Value

Unadjusted raw concentrations (±SD)
Elecsys Aβ42, pg/mL

81

1,271 ± 703

758

1,277 ± 647

N.S.

Elecsys tTau, pg/mL

81

182 ± 77

758

253 ± 120

<0.0001

Elecsys pTau, pg/mL

81

16.6 ± 7.3

758

23.6 ± 13.4

<0.0001

INNOTEST Aβ42, pg/mL

10

893 ± 315

110

927 ± 340

N.S.

INNOTEST tTau, pg/mL

10

253 ± 123

110

411 ± 248

0.02

INNOTEST pTau, pg/mL

10

46.2 ± 18.2

110

66.5 ± 32.1

0.02

NfL, pg/mL

90

1,363 ± 755

853

1,837 ± 1,281

<0.0001

sTREM2, pg/mL

91

1,336 ± 470

868

1,856 ± 624

<0.0001

Unadjusted natural logarithm-transformed values (±SD)
Elecsys Aβ42

81

7.00 ± 0.56

758

7.02 ± 0.53

N.S.

Elecsys tTau

81

5.12 ± 0.39

758

5.44 ± 0.43

<0.0001

Elecsys pTau

81

2.73 ± 0.39

758

3.04 ± 0.48

<0.0001

NfL

90

7.10 ± 0.48

853

7.37 ± 0.51

<0.0001

sTREM2

91

7.13 ± 0.40

868

7.47 ± 0.32

<0.0001

Covariate-adjusted natural logarithm-transformed values (±SE)
Elecsys Aβ42

81

6.79 ± 0.08

758

6.92 ± 0.03

0.10

Elecsys tTau

81

5.28 ± 0.07

758

5.53 ± 0.03

<0.0001

Elecsys pTau

81

2.87 ± 0.08

758

3.12 ± 0.04

<0.0001

NfL

90

7.21 ± 0.08

853

7.44 ± 0.03

0.0005

sTREM2

91

7.38 ± 0.07

868

7.66 ± 0.03

<0.0001

Abbreviations: AA = African American; Aβ42 = amyloid-β 42; NfL = neurofilament light chain; NHW = non-Hispanic White; N.S. = not significant; pTau =
phosphorylated tau181; sTREM2 = soluble triggering receptor expressed on myeloid cells 2; tTau = total tau.
CSF biomarker values were transformed with the natural logarithm. The significance of differences in CSF biomarker values between AA and NHW participants was calculated by Mann-Whitney tests for unadjusted raw values and Student t tests for unadjusted natural logarithm-transformed values. For each
CSF biomarker, the natural logarithm-transformed value was the outcome variable in an analysis of covariance model with the following predictor variables:
race (AA or NHW), centered age (the age at CSF collection minus the mean age for the cohort [69.0 years]), sex, years of education (≤12 and >12 years of
education), family history of dementia (positive or negative), APOE e4 status (e4 carrier or noncarrier), dementia status (CDR = 0 or CDR >0), and every 2-way
interaction among these variables. The estimated natural logarithm-transformed biomarker value for each race, adjusted for covariates, and the significance
of race as a predictor variable (p value) in the model is shown.

CSF sTREM2 levels. Signiﬁcant and reproducible diﬀerences
in the frequencies of genetic variants between AA and NHW
groups are unlikely to be explained by nonbiological factors,
but the eﬀects of these genetic diﬀerences on CSF sTREM2
concentrations could be susceptible to many nonbiological
inﬂuences. Reasons for racial diﬀerences may include diﬀerences in social, geopolitical, and environmental factors, some
of which may be related to systemic racism. These include
disparities in socioeconomic status,7 education,8 and stress.9
Diﬀerences in medical comorbidities and physiology, such as
the prevalence of cerebrovascular disease,1 may also contribute. Notably, some of these conditions may aﬀect risk for AD
dementia.1 The eﬀects of these factors on CSF sTREM2 are
unknown. Neither the Knight ADRC nor the ADNI data set
currently includes detailed information about social
Neurology.org/NG

determinants of health such as economic stability, access to
healthy foods, neighborhood safety, and quality of education.
Studies are needed that include much larger numbers of AA
with detailed sociocultural and environmental data.31
The role of TREM2 in AD has been an active area of investigation because TREM2 variants were found to be associated with the risk of symptomatic AD.13,14 TREM2 is a
microglial receptor that binds amyloid with high aﬃnity and
may mediate the inﬂammatory response to amyloid
plaques.11,12 Higher TREM2 levels may ameliorate the eﬀects
of AD pathology,32 potentially by decreasing neuritic
dystrophy33,34 and limiting spreading of pathologic tau
seeds.35 CSF sTREM2 concentrations are not linearly associated with AD brain pathology, but are thought to peak
Neurology: Genetics | Volume 7, Number 2 | April 2021
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Table 4 CSF Biomarker Values of Individuals in the Alzheimer’s Disease Neuroimaging Initiative Cohort

Characteristic

AA participants

NHW participants

n

n

p Value

Unadjusted raw values (±SD)
Elecsys CSF Aβ42, pg/mL

23

1,179 ± 601

916

1,049 ± 592

N.S.

Elecsys CSF tTau, pg/mL

23

283 ± 141

914

292 ± 126

N.S.

Elecsys CSF pTau, pg/mL

23

28.1 ± 16.1

914

28.1 ± 14.1

N.S.

CSF NfL, pg/mL

8

1,050 ± 558

292

1,499 ± 943

0.09

CSF sTREM2, pg/mL

23

3,007 ± 1,541

917

4,128 ± 1,876

0.001

Unadjusted natural logarithm-transformed values (±SD)
Elecsys CSF Aβ42

23

6.92 ± 0.6

916

6.81 ± 0.5

N.S.

Elecsys CSF tTau

23

5.56 ± 0.4

914

5.59 ± 0.4

N.S.

Elecsys CSF pTau

23

3.22 ± 0.5

914

3.22 ± 0.5

N.S.

CSF NfL

8

6.89 ± 0.4

292

7.18 ± 0.4

0.07

CSF sTREM2

23

7.91 ± 0.4

917

8.22 ± 0.5

0.001

917

8.21 ± 0.03

0.03

Covariate-adjusted natural logarithm-transformed values (±SE)
CSF sTREM2

23

7.87 ± 0.15

Abbreviations: AA = African American; Aβ42 = amyloid-β 42; NfL = neurofilament light chain; NHW = non-Hispanic White; N.S. = not significant; pTau =
phosphorylated tau181; sTREM2 = soluble triggering receptor expressed on myeloid cells 2; tTau = total tau.
CSF biomarker values were transformed with the natural logarithm. The significance of differences in CSF biomarker values between AA and NHW participants was calculated by Mann-Whitney tests for unadjusted raw values and Student t tests for unadjusted natural logarithm-transformed values. For each
CSF biomarker, the natural logarithm-transformed value was the outcome variable in an analysis of covariance model with the following predictor variables:
race (AA or NHW), centered age (the age at CSF collection minus the mean age for the cohort [69.0 years]), sex, years of education (≤12 and >12 years of
education), APOE e4 status (e4 carrier or noncarrier), dementia status (CDR = 0 or CDR >0), and every 2-way interaction among these variables. The estimated
natural logarithm-transformed biomarker value for each race, adjusted for covariates, and the significance of race as a predictor variable (p value) in the
model is shown.

shortly after AD symptom onset and then plateau or decrease.36 In our mostly cognitively normal cohort, we found
overall lower concentrations of CSF sTREM2 in individuals
carrying coding variants in TREM2, but these concentrations
may later rise in response to AD pathology. One recent study
(that did not account for race) demonstrated that lower
baseline CSF sTREM2 is associated with faster cognitive
decline in participants with symptomatic AD20; given our
ﬁnding of lower average CSF sTREM2 in AA, this suggests
that AA with AD may decline more rapidly.
TREM2 is a therapeutic target for AD, and an anti-TREM2
antibody is being tested in an AD clinical trial.37 TREM2 may also
inﬂuence antiamyloid treatments for AD—1 study found that
genetic deletion of TREM2 reduced antiamyloid monoclonal
antibody–mediated clearance of amyloid plaques in cell culture
experiments.38 Given the ﬁndings of this study that AAs have
lower average CSF sTREM2, this prompts the hypothesis that
poor clearance of amyloid plaques by antiamyloid monoclonal
antibodies may be more common in AA. If true, this diﬀerence
may not readily be discerned because AAs are severely underrepresented (<3%) in many recent drug trials for AD.39,40 In
addition, because TREM2 is expressed not only in the brain, but
also throughout the body in multiple myeloid cells,41 studies are
8
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needed to examine whether racial diﬀerences in the frequencies of
TREM2 coding variants and rs1582763 (A) translate to racial
diﬀerences in other inﬂammatory conditions.
Some studies have found that AAs are at higher risk for AD
dementia,42,43 although this is unclear, and the relationship
between race and AD is likely very complex.44 Previous work
has suggested that signiﬁcant diﬀerences in AD pathophysiology exist between AA and NHW groups.2–5 In addition to
our ﬁndings related to TREM2, we conﬁrmed previous
ﬁndings using more precise automated immunoassays that
AAs had lower average CSF tTau and pTau.2,4 We additionally found lower average NfL in AA compared with NHW
groups. CSF NfL is a nonspeciﬁc marker of neuroxonal
damage, and like tTau and pTau, NfL is typically elevated in
AD.45 The lower average levels of CSF tTau, pTau, and NfL in
the AA compared with the NHW group, even when average
CSF Aβ42 levels were not diﬀerent between the groups, could
indicate that AAs are less likely to develop neuronal damage in
response to brain amyloid. It is unclear how these racial differences in CSF biomarkers relate to risk for AD dementia.
A major limitation of most AD studies is the underrepresentation of racial and ethnic minorities. Our study
Neurology.org/NG

Figure 2 Differences in CSF sTREM2 Levels in the Knight Alzheimer Disease Research Center Cohort by Self-Reported Race

The natural logarithm of CSF concentrations of soluble triggering receptor expressed on myeloid cells 2 (sTREM2) was plotted as a function of TREM2 coding
variant (A), MS4A4A rs1582763 genotype (B), or TREM2 coding variant status and MS4A4A rs1582763 (A) carrier status (C). For all plots, the corresponding
sTREM2 concentrations in pg/mL are shown on the right axis. Red squares represent samples from African Americans (AAs), and gray circles represent
samples from non-Hispanic Whites (NHWs). Horizontal dashed lines indicate the mean sTREM2 levels for AA (red) and NHW (gray) groups. Vertical dotted lines
separate genetic groups. The number of individuals in each group is listed (n).

used the Knight ADRC cohort, which includes one of the
largest groups of AAs in AD research with both CSF biomarker and genetic data, but AAs were still underrepresented.
Adequate representation of racial minorities in research
studies is a challenge nationally due in part to historical abuses
by researchers resulting in the mistrust of medical research by
racial minority communities.46 Furthermore, deeply ﬂawed
and malignant suppositions about genetic diﬀerences between
races have been used to oppress minority groups, especially
AA.47 Race can be an uncomfortable topic for some
Neurology.org/NG

researchers and clinicians to discuss and study. However, it is
imperative to study racial diﬀerences, including racial diﬀerences related to genetics, because they may inﬂuence AD
pathophysiology, diagnosis, treatment eﬃcacy, and outcomes.
For example, applying cutoﬀs formulated with data from
NHW cohorts could increase the frequency of AD misdiagnosis in AA patients.5 Even more concerning, AD clinical
trials with inadequate representation of AA may lead to development of AD therapies that are less likely to be safe or
eﬀective in AA as has occurred in other conditions such as
Neurology: Genetics | Volume 7, Number 2 | April 2021
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hypertension.48 Development of AD therapies that are less
likely to be eﬀective in AA would further compound longstanding injustices experienced by AA. This study underscores the importance of carefully evaluating the eﬀects of race
on AD pathophysiology.
Acknowledgment
The authors express their gratitude to the research volunteers
who participated in the studies from which these data were
obtained and their supportive families. They thank the Clinical,
Fluid Biomarker and Imaging Cores at the Knight ADRC for
sample and data collection. They also thank Dr. Brian A. Gordon
at Washington University for helpful discussions.
Study Funding
This study was supported by National Institute on Aging
grants R03AG050921 and K23AG053426 (S.E. Schindler),
T32AG000213 (Y. Deming), RF1AG058501 (C. Cruchaga
and L. Piccio), R01AG054567 (T.L.S. Benzinger and Y.
Wang), P50AG005681 (J.C. Morris), P01AG003991 (J.C.
Morris), P01AG026276 (J.C. Morris), the Foundation for
Barnes-Jewish Hospital (J.C. Morris), and the Cure Alzheimers Fund (K.L. Moulder). L. Piccio was supported by a
grant from the Fondazione Italiana Sclerosi Multipla (FISM
2017/R/20) and coﬁnanced with the 5 per mille public
funding. For the replication cohort from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI), data collection and
sharing were funded by the ADNI (NIH Grant U01
AG024904) and DOD ADNI (Department of Defense award
number W81XWH-12-2- 0012). The ADNI is funded by the
National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous
contributions from the following: AbbVie, Alzheimers Association; Alzheimers Drug Discovery Foundation; Araclon
Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb
Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F.
HoﬀmannLa Roche Ltd and its aﬃliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen
Alzheimer Immunotherapy Research & Development, LLC.;
Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.;
Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation;
Pﬁzer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical
Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support
ADNI clinical sites in Canada. Private sector contributions are
facilitated by the Foundation for the NIH (fnih.org). The
grantee organization is the Northern California Institute for
Research and Education, and the study is coordinated by the
Alzheimers Therapeutic Research Institute at the University
of Southern California. ADNI data are disseminated by the
Laboratory for Neuro Imaging at the University of Southern
California.

10

Neurology: Genetics | Volume 7, Number 2 | April 2021

Disclosure
S.E. Schindler reports no disclosures relevant to the
manuscript. C. Cruchaga receives research support from
Biogen, EISAI, Alector, and Parabon and is a member of
the advisory board of ADx Healthcare, Halia Therapeutics,
and Vivid Genomics. A. Joseph, L. McCue, F.H.G. Farias,
C.H. Wilkins, Y. Deming, R.L. Henson, and R.J. Mikesell
report no disclosures relevant to the manuscript. L. Piccio
receives research support from Alector. J.J. Llibre-Guerra
and K.L. Moulder report no disclosures relevant to the
manuscript. A.M. Fagan has received research funding
from Biogen, Fujirebio, and Roche Diagnostics; she is a
member of the scientiﬁc advisory boards for Roche Diagnostics, Genentech, and AbbVie; and she consults for
Araclon/Grifols, DiademRes, DiamiR, and Otsuka Pharmaceuticals. B.M. Ances reports no disclosures relevant to
the manuscript. T.L.S. Benzinger has received research
support from Avid Radiopharmaceuticals (a wholly owned
subsidiary of Eli Lilly) and Biogen; she has or is currently
participating in clinical trials sponsored by Janssen, Eli
Lilly, Pﬁzer, Biogen, and Roche; and she has received travel
support from Biogen, the American Society for Neuroradiology, the Alzheimer’s Association, and the People’s
Republic of China. C. Xiong reports no disclosures relevant to the manuscript. D.M. Holtzman cofounded and is
on the scientiﬁc advisory board of C2N Diagnostics.
Washington University and D.M. Holtzman have equity
ownership interest in C2N Diagnostics and receive royalty
income based on technology (stable isotope labeling kinetics and blood plasma assay) licensed by Washington
University to C2N Diagnostics; he receives income from
C2N Diagnostics for serving on the scientiﬁc advisory
board; he is on the scientiﬁc advisory board of Denali and
Genentech and consults for Merck and Idorsia; his laboratory receives research support from C2N Diagnostics
and NextCure. J.C. Morris is the Chair of the Research
Strategy Council of the Cure Alzheimer’s Fund. Go to
Neurology.org/NG for full disclosures.
Publication History
Received by Neurology: Genetics October 22, 2020. Accepted in ﬁnal
form January 20, 2021.

Appendix Authors
Name

Location

Contribution

Suzanne E.
Schindler,
MD, PhD

Washington University,
St. Louis, MO

Drafting/revision of the
manuscript for content,
including medical writing for
content; major role in the
acquisition of data; study
concept or design; and
analysis or interpretation of
data

Neurology.org/NG

Appendix

Appendix

(continued)

(continued)

Name

Location

Contribution

Name

Location

Contribution

Carlos
Cruchaga,
PhD

Washington University,
St. Louis, MO

Drafting/revision of the
manuscript for content,
including medical writing for
content; major role in the
acquisition of data; and
analysis or interpretation of
data

Anne M.
Fagan, PhD

Washington University,
St. Louis, MO

Drafting/revision of the
manuscript for content,
including medical writing for
content; major role in the
acquisition of data; and
analysis or interpretation of
data

Amulya
Joseph, BA

Washington University,
St. Louis, MO

Drafting/revision of the
manuscript for content,
including medical writing for
content, and analysis or
interpretation of data

Beau M.
Ances, MD,
PhD

Washington University,
St. Louis, MO

Drafting/revision of the
manuscript for content,
including medical writing for
content, and analysis or
interpretation of data

Lena McCue,
PhD

Washington University,
St. Louis, MO

Drafting/revision of the
manuscript for content,
including medical writing for
content; analysis or
interpretation of data; and
statistical analysis

Tammie L.S.
Benzinger,
MD, PhD

Washington University,
St. Louis, MO

Drafting/revision of the
manuscript for content,
including medical writing for
content, and analysis or
interpretation of data

Fabiana H.G.
Farias, PhD

Washington University,
St. Louis, MO

Drafting/revision of the
manuscript for content,
including medical writing for
content; major role in the
acquisition of data; and
analysis or interpretation of
data

Chengjie
Xiong, PhD

Washington University,
St. Louis, MO

Drafting/revision of the
manuscript for content,
including medical writing for
content; study concept or
design; analysis or
interpretation of data; and
statistical analysis

Consuelo H.
Wilkins, MD,
MSci

Vanderbilt University and
Meharry Medical College,
Nashville, TN

Drafting/revision of the
manuscript for content,
including medical writing for
content, and analysis or
interpretation of data

David M.
Holtzman,
MD

Washington University,
St. Louis, MO

Drafting/revision of the
manuscript for content,
including medical writing for
content, and analysis or
interpretation of data

Yuetiva
Deming,
PhD

University of Wisconsin,
Madison

Drafting/revision of the
manuscript for content,
including medical writing for
content, and analysis or
interpretation of data

John C.
Morris, MD

Washington University,
St. Louis, MO

Rachel L.
Henson, MS

Washington University,
St. Louis, MO

Drafting/revision of the
manuscript for content,
including medical writing for
content; major role in the
acquisition of data; and
analysis or interpretation of
data

Drafting/revision of the
manuscript for content,
including medical writing for
content; major role in the
acquisition of data; study
concept or design; and
analysis or interpretation of
data

Robert J.
Mikesell, BS

Laura Piccio,
MD, PhD

Washington University,
St. Louis, MO

University of Sydney,
Australia

Jorge J.
LlibreGuerra, MD,
MSc

Washington University,
St. Louis, MO

Krista L.
Moulder,
PhD

Washington University,
St. Louis, MO

Drafting/revision of the
manuscript for content,
including medical writing for
content, and major role in
the acquisition of data
Drafting/revision of the
manuscript for content,
including medical writing for
content; major role in the
acquisition of data; and
analysis or interpretation of
data
Drafting/revision of the
manuscript for content,
including medical writing for
content, and analysis or
interpretation of data
Drafting/revision of the
manuscript for content,
including medical writing for
content, and analysis or
interpretation of data

References
1.

2.

3.
4.
5.

6.
7.
8.

9.

10.

11.
12.

Neurology.org/NG

Babulal GM, Quiroz YT, Albensi BC, et al. Perspectives on ethnic and racial disparities
in Alzheimer’s disease and related dementias: update and areas of immediate need.
Alzheimers Dement 2019;15:292–312.
Howell JC, Watts KD, Parker MW, et al. Race modiﬁes the relationship between
cognition and Alzheimer’s disease cerebrospinal ﬂuid biomarkers. Alzheimers Res
Ther 2017;9:88.
Gottesman RF, Schneider AL, Zhou Y, et al. The ARIC-PET amyloid imaging study:
brain amyloid diﬀerences by age, race, sex, and APOE. Neurology 2016;87:473–480.
Morris JC, Schindler SE, McCue LM, et al. Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol 2019;76:264–273.
Garrett SL, McDaniel D, Obideen M, et al. Racial disparity in cerebrospinal ﬂuid
amyloid and tau biomarkers and associated cutoﬀs for mild cognitive impairment.
JAMA Netw Open 2019;2:e1917363.
Bonham VL, Green ED, Perez-Stable EJ. Examining how race, ethnicity, and ancestry
data are used in biomedical research. JAMA 2018;320:1533–1534.
Yaﬀe K, Falvey C, Harris TB, et al. Eﬀect of socioeconomic disparities on incidence of
dementia among biracial older adults: prospective study. BMJ 2013;347:f7051.
Gross AL, Mungas DM, Crane PK, et al. Eﬀects of education and race on cognitive
decline: an integrative study of generalizability versus study-speciﬁc results. Psychol
Aging 2015;30:863–880.
Gilsanz P, Quesenberry CP Jr, Mayeda ER, Glymour MM, Farias ST, Whitmer RA.
Stressors in midlife and risk of dementia: the role of race and education. Alzheimer Dis
Assoc Disord 2019;33:200–205.
Reitz C, Jun G, Naj A, et al. Variants in the ATP-binding cassette transporter
(ABCA7), apolipoprotein E 4,and the risk of late-onset Alzheimer disease in African
Americans. JAMA 2013;309:1483–1492.
Wang Y, Cella M, Mallinson K, et al. TREM2 lipid sensing sustains the microglial
response in an Alzheimer’s disease model. Cell 2015;160:1061–1071.
Zhao Y, Wu X, Li X, et al. TREM2 is a receptor for beta-amyloid that mediates
microglial function. Neuron 2018;97:1023–1031.e7.

Neurology: Genetics | Volume 7, Number 2 | April 2021

11

13.
14.
15.
16.
17.
18.
19.

20.

21.

22.
23.

24.

25.
26.

27.

28.
29.

30.

12

Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer’s disease. N Engl J
Med 2013;368:117–127.
Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk
of Alzheimer’s disease. N Engl J Med 2013;368:107–116.
Jin SC, Benitez BA, Karch CM, et al. Coding variants in TREM2 increase risk for
Alzheimer’s disease. Hum Mol Genet 2014;23:5838–5846.
Ulrich JD, Holtzman DM. TREM2 function in Alzheimer’s disease and neurodegeneration. ACS Chem Neurosci 2016;7:420–427.
Jin SC, Carrasquillo MM, Benitez BA, et al. TREM2 is associated with increased risk
for Alzheimer’s disease in African Americans. Mol Neurodegener 2015;10:19.
Del-Aguila JL, Benitez BA, Li Z, et al. TREM2 brain transcript-speciﬁc studies in AD
and TREM2 mutation carriers. Mol Neurodegener 2019;14:18.
Kleinberger G, Yamanishi Y, Suarez-Calvet M, et al. TREM2 mutations implicated in
neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med
2014;6:243ra286.
Ewers M, Franzmeier N, Suarez-Calvet M, et al. Increased soluble TREM2 in cerebrospinal ﬂuid is associated with reduced cognitive and clinical decline in Alzheimer’s
disease. Sci Transl Med 2019;11:eaav6221.
Piccio L, Deming Y, Del-Aguila JL, et al. Cerebrospinal ﬂuid soluble TREM2 is higher
in Alzheimer disease and associated with mutation status. Acta Neuropathol 2016;
131:925–933.
Deming Y, Filipello F, Cignarella F, et al. The MS4A gene cluster is a key modulator of
soluble TREM2 and Alzheimer’s disease risk. Sci Transl Med 2019;11:eaau2291.
Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals
identiﬁes 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 2013;45:
1452–1458.
Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and
cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer
Dis Assoc Disord 2006;20:210–216.
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules.
Neurology 1993;43:2412–2414.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for
grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:
189–198.
Cruchaga C, Kauwe JS, Mayo K, et al. SNPs associated with cerebrospinal ﬂuid
phospho-tau levels inﬂuence rate of decline in Alzheimer’s disease. PLoS Genet 2010;
6:e1001101.
Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
PLINK: rising to the challenge of larger and richer datasets. Gigascience 2015;4:7.
Pemberton TJ, Wang C, Li JZ, Rosenberg NA. Inference of unexpected genetic
relatedness among individuals in HapMap Phase III. Am J Hum Genet 2010;87:
457–464.
Schindler SE, Gray JD, Gordon BA, et al. Cerebrospinal ﬂuid biomarkers measured by
Elecsys assays compared to amyloid imaging. Alzheimers Dement 2018;14:
1460–1469.

Neurology: Genetics | Volume 7, Number 2 | April 2021

31.

32.

33.
34.

35.
36.

37.
38.
39.
40.
41.
42.

43.

44.

45.

46.

47.
48.

Wilkins CH, Schindler SE, Morris JC. Addressing health disparities among minority
populations: why clinical trial recruitment is not enough. JAMA Neurol 2020;77:
1063–1064.
Lee CYD, Daggett A, Gu X, et al. Elevated TREM2 gene dosage reprograms microglia
responsivity and ameliorates pathological phenotypes in Alzheimer’s disease models.
Neuron 2018;97:1032–1048.e5.
Wang Y, Ulland TK, Ulrich JD, et al. TREM2-mediated early microglial response
limits diﬀusion and toxicity of amyloid plaques. J Exp Med 2016;213:667–675.
Yuan P, Condello C, Keene CD, et al. TREM2 haplodeﬁciency in mice and humans
impairs the microglia barrier function leading to decreased amyloid compaction and
severe axonal dystrophy. Neuron 2016;92:252–264.
Leyns CEG, Gratuze M, Narasimhan S, et al. TREM2 function impedes tau seeding in
neuritic plaques. Nat Neurosci 2019;22:1217–1222.
Suarez-Calvet M, Kleinberger G, Araque Caballero MA, et al. sTREM2 cerebrospinal ﬂuid
levels are a potential biomarker for microglia activity in early-stage Alzheimer’s disease and
associate with neuronal injury markers. EMBO Mol Med 2016;8:466–476.
Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement 2019;5:272–293.
Xiang X, Werner G, Bohrmann B, et al. TREM2 deﬁciency reduces the eﬃcacy of
immunotherapeutic amyloid clearance. EMBO Mol Med 2016;8:992–1004.
Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due
to Alzheimer’s disease. N Engl J Med 2018;378:321–330.
Egan MF, Kost J, Tariot PN, et al. Randomized trial of verubecestat for mild-tomoderate Alzheimer’s disease. N Engl J Med 2018;378:1691–1703.
Kober DL, Brett TJ. TREM2-ligand interactions in health and disease. J Mol Biol
2017;429:1607–1629.
Steenland K, Goldstein FC, Levey A, Wharton W. A meta-analysis of Alzheimer’s
disease incidence and prevalence comparing African-Americans and Caucasians.
J Alzheimers Dis 2016;50:71–76.
Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia
incidence between six racial and ethnic groups over 14 years. Alzheimers Dement
2016;12:216–224.
Xiong C, Luo J, Coble D, Agboola F, Kukull W, Morris JC. Complex interactions
underlie racial disparity in the risk of developing Alzheimer’s disease dementia. Alzheimers Dement 2020;16:589–597.
Bridel C, van Wieringen WN, Zetterberg H, et al. Diagnostic value of cerebrospinal
ﬂuid neuroﬁlament light protein in neurology: a systematic review and meta-analysis.
JAMA Neurol 2019;76:1035–1048.
George S, Duran N, Norris K. A systematic review of barriers and facilitators to
minority research participation among African Americans, Latinos, Asian Americans,
and Paciﬁc Islanders. Am J Public Health 2014;104:e16–e31.
Pernick MS. Eugenics and public health in American history. Am J Public Health
1997;87:1767–1772.
Wu J, Kraja AT, Oberman A, et al. A summary of the eﬀects of antihypertensive
medications on measured blood pressure. Am J Hypertens 2005;18:935–942.

Neurology.org/NG

African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic
Variants
Suzanne E. Schindler, Carlos Cruchaga, Amulya Joseph, et al.
Neurol Genet 2021;7;
DOI 10.1212/NXG.0000000000000571
This information is current as of March 4, 2021

Neurol Genet is an official journal of the American Academy of Neurology. Published since April 2015, it is
an open-access, online-only, continuous publication journal. Copyright Copyright © 2021 The Author(s).
Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights
reserved. Online ISSN: 2376-7839.

Updated Information &
Services

including high resolution figures, can be found at:
http://ng.neurology.org/content/7/2/e571.full.html

References

This article cites 48 articles, 6 of which you can access for free at:
http://ng.neurology.org/content/7/2/e571.full.html##ref-list-1

Citations

This article has been cited by 2 HighWire-hosted articles:
http://ng.neurology.org/content/7/2/e571.full.html##otherarticles

Subspecialty Collections

This article, along with others on similar topics, appears in the
following collection(s):
All Immunology
http://ng.neurology.org//cgi/collection/all_immunology
Alzheimer's disease
http://ng.neurology.org//cgi/collection/alzheimers_disease
Association studies in genetics
http://ng.neurology.org//cgi/collection/association_studies_in_genetics
Health disparities
http://ng.neurology.org//cgi/collection/health_disparities

Errata

An erratum has been published regarding this article. Please see next
page or:
/content/7/3/e594.full.pdf

Permissions & Licensing

Information about reproducing this article in parts (figures,tables) or in
its entirety can be found online at:
http://ng.neurology.org/misc/about.xhtml#permissions

Reprints

Information about ordering reprints can be found online:
http://ng.neurology.org/misc/addir.xhtml#reprintsus

Neurol Genet is an official journal of the American Academy of Neurology. Published since April 2015, it is
an open-access, online-only, continuous publication journal. Copyright Copyright © 2021 The Author(s).
Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights
reserved. Online ISSN: 2376-7839.

CORRECTION

African Americans Have Diﬀerences in CSF Soluble TREM2 and
Associated Genetic Variants
Neurol Genet 2021;7:e594. doi:10.1212/NXG.0000000000000594

In the article “African Americans Have Diﬀerences in CSF Soluble TREM2 and Associated
Genetic Variants” by Schindler et al.,1 there were errors in the x-axis of ﬁgure 2C. The third label
from the left should read, “TREM2 variant noncarrier rs1582763 (A) noncarrier AA (n = 63)”;
the ﬁfth label should read, “TREM2 variant carrier rs1582763 (A) carrier AA (n = 1)”; the sixth
label should read “TREM2 variant carrier rs1582763 (A) carrier NHW (n = 21)”; and the
eighth label should read, “TREM2 variant noncarrier rs1582763 (A) carrier NHW (n = 492).”
The correct ﬁgure is published here. The editorial staﬀ regret the errors.
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